| Wed 7 Sep 2022, 17:02 | | MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings |
|
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
7 September 2022
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Name City of registered office Country of registered office
J.P. Morgan Securities plc
5. Date on which the threshold was crossed or reached
05-Sep-2022
6. Date on which Issuer notified
07-Sep-2022
7. Total positions of person(s) subject to the notification
obligation
% of voting
% of voting rights through
rights attached financial Total of both Total number of
to shares (total instruments in % (8.A + voting rights
of 8.A) (total of 8.B 1 + 8.B) held in issuer
8.B 2)
Resulting
situation on the
date on which
4.414499 1.987828 6.402327 47200756
threshold was
crossed or
reached
Position of
previous
5.295136 1.824894 7.120030
notification (if
applicable)
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of Number of Number of indirect % of direct
shares ISIN direct voting voting rights voting rights % of indirect voting
code(if possible) rights (DTR5.1) (DTR5.2.1) (DTR5.1) rights (DTR5.2.1)
GB00B8HX8Z88 32545622 4.414499
Sub Total 8.A 32545622 4.414499%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Number of voting rights that
may be acquired if the % of
Type of financial Expiration Exercise/conversion instrument is voting
instrument date period exercised/converted rights
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
Type of Physical or
financial Exercise/conversion cash Number of % of voting
instrument Expiration date period settlement voting rights rights
Cash-
settled
16/09/2022 16/09/2022 Cash 2628232 0.356494
Equity
Swap
Cash-
settled
26/10/2022 26/10/2022 Cash 1408000 0.190982
Equity
Swap
Cash- 28/10/2022 28/10/2022 Cash 3241439 0.439670
settled
Equity
Swap
Cash-
settled
23/11/2022 23/11/2022 Cash 58635 0.007953
Equity
Swap
Cash-
settled
01/02/2023 01/02/2023 Cash 16152 0.002191
Equity
Swap
Cash-
settled
02/06/2023 02/06/2023 Cash 143409 0.019452
Equity
Swap
Cash-
settled
04/07/2023 04/07/2023 Cash 7056873 0.957197
Equity
Swap
Cash-
settled
12/07/2023 12/07/2023 Cash 3076 0.000417
Equity
Swap
Cash-
settled
09/08/2023 09/08/2023 Cash 759 0.000103
Equity
Swap
Cash-
settled
18/08/2023 18/08/2023 Cash 145 0.000020
Equity
Swap
Cash-
settled
22/08/2023 22/08/2023 Cash 598 0.000081
Equity
Swap
Cash-
settled
06/09/2023 06/09/2023 Cash 8277 0.001123
Equity
Swap
Cash- 03/10/2023 03/10/2023 Cash 5518 0.000748
settled
Equity
Swap
Cash-
settled
04/10/2023 04/10/2023 Cash 3512 0.000476
Equity
Swap
Cash-
settled
27/10/2023 27/10/2023 Cash 2820 0.000383
Equity
Swap
Cash-
settled
12/02/2024 12/02/2024 Cash 77091 0.010457
Equity
Swap
Cash-
settled
06/07/2027 06/07/2027 Cash 309 0.000042
Equity
Swap
Cash-
settled
03/08/2027 03/08/2027 Cash 289 0.000039
Equity
Swap
Sub Total 8.B2 14655134 1.987828%
9. Information in relation to the person subject to the
notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
% of voting
rights through
% of voting financial
rights if it equals instruments if it Total of both if it
or is higher than equals or is higher equals or is higher
Ultimate Name of controlled the notifiable than the than the notifiable
controlling person undertaking threshold notifiable threshold
threshold
JPMorgan J.P. Morgan
Chase & Co. Securities plc 3.343113 5.330941%
JPMorgan
JPMorgan Chase Bank,
Chase & Co. National
Association
J.P. Morgan
Equities
JPMorgan South Africa
Chase & Co. Proprietary
Limited
J.P. Morgan
JPMorgan Securities
Chase & Co. LLC
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)
JPMorgan Chase & Co.
JPMorgan Chase Holdings LLC (100%)
J.P. Morgan Broker-Dealer Holdings Inc. (100%)
J.P. Morgan Securities LLC (100%)
12. Date of Completion
07-Sep-2022
13. Place Of Completion
London
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day
case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle
East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient
beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital
in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 07-09-2022 05:02:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
